Abivax Current Deferred Revenue from 2010 to 2026
| ABVX Stock | 117.67 6.96 6.29% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 59.8 K | Current Value 62.8 K | Quarterly Volatility 5.1 M |
Check Abivax SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abivax SA's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 3 M or Selling General Administrative of 39.8 M, as well as many indicators such as Price To Sales Ratio of 33.77, Dividend Yield of 0.0 or PTB Ratio of 7.67. Abivax financial statements analysis is a perfect complement when working with Abivax SA Valuation or Volatility modules.
Abivax | Current Deferred Revenue | Build AI portfolio with Abivax Stock |
The evolution of Current Deferred Revenue for Abivax SA American provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Abivax SA compares to historical norms and industry peers.
Latest Abivax SA's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Abivax SA American over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Abivax SA's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abivax SA's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Abivax Current Deferred Revenue Regression Statistics
| Arithmetic Mean | (1,157,554) | |
| Geometric Mean | 481,553 | |
| Coefficient Of Variation | (444.64) | |
| Mean Deviation | 3,017,282 | |
| Median | 162,000 | |
| Standard Deviation | 5,146,930 | |
| Sample Variance | 26.5T | |
| Range | 19.9M | |
| R-Value | (0.12) | |
| Mean Square Error | 27.8T | |
| R-Squared | 0.01 | |
| Significance | 0.64 | |
| Slope | (123,199) | |
| Total Sum of Squares | 423.9T |
Abivax Current Deferred Revenue History
About Abivax SA Financial Statements
Abivax SA investors use historical fundamental indicators, such as Abivax SA's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Abivax SA. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 59.8 K | 62.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Abivax Stock Analysis
When running Abivax SA's price analysis, check to measure Abivax SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abivax SA is operating at the current time. Most of Abivax SA's value examination focuses on studying past and present price action to predict the probability of Abivax SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abivax SA's price. Additionally, you may evaluate how the addition of Abivax SA to your portfolios can decrease your overall portfolio volatility.